The personal journeys of six people in the United Kingdom living with HIV, hepatitis C and cancer – and the challenges they face due to stigma and health inequities – come together in the form of a new, intentionally difficult-to-read book from Gilead.
Responsible Business & Employee Engagement
| Gilead Sciences
When employees at Gilead’s recently opened New Jersey office need a place to meet, the “Cara” conference room is one such place they gather. Given the room’s namesake, it’s especially fitting when the topic at hand is the company’s oncology work.
Philanthropy & Cause Initiatives
| Gilead Sciences
Nearly 36 years ago the AIDS Memorial Quilt was displayed for the first time to memorialize and physically represent lives lost to HIV. Gilead has always actively supported the Quilt, and creating a new panel made sense for a company dedicated to helping end the HIV epidemic.
Dr. Shringar Rao’s inquisitive nature and dedication to addressing health inequities drive her eagerness to help advance innovative scientific breakthroughs.
When Shirley Cantin was a law student, about half of her classmates were women. Yet when she joined a corporate law firm, Shirley noticed that most of its leaders were white men. And when she left a decade later, little progress on the leadership team’s diversity had been made.
Gilead Sciences, Inc. announced it will present new data at San Antonio Breast Cancer Symposium 2023, supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer and pre-treated HR+/HER2- metastatic breast cancer patients.
Nearly 36 years ago the AIDS Memorial Quilt was displayed for the first time to memorialize and physically represent lives lost to HIV. Gilead has always actively supported the Quilt, and creating a new panel made sense for a company dedicated to helping end the HIV epidemic.
Through our community partnerships in low-and-middle-income countries, we are working together to expand access and reduce barriers to care while embracing innovation.
We're proud to have contributed to this milestone announced by the World Health Organization - marking the elimination of visceral leishmaniasis (VL) as a public health problem in Bangladesh.
Since the pledge, Gilead has continued its long history in supporting reducing deaths from VL and controlling other neglected tropical diseases such as cryptococcal meningitis in efforts to advance global health equity.
Dr. Shringar Rao’s inquisitive nature and dedication to addressing health inequities drive her eagerness to help advance innovative scientific breakthroughs.
Claudia Hardy says she’s found her life’s mission. As director of Community Health Access and Relations for the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, she brings cancer resources and preventive care to communities.
Gilead Sciences, Inc. (Nasdaq: GILD) was recognized as the number one philanthropic funder of HIV-related programs for the second year in a row, in a new report released by Funders Concerned About AIDS (FCAA).
Shortly after Sandra joined Gilead, this company ambition touched close to home. She worked on an acquisition that ended up being the backbone of Gilead’s work to develop a cure for hepatitis C.
Gilead’s Corporate Social Responsibility (CSR) Report provides an overview of the work the company is doing around the world to improve the lives of...